PDF(1805 KB)
Association of age distribution with the expression of angiotensin-converting enzyme 2 in lung tissues in severe acute respiratory syndrome coronavirus 2 infection: reflections from the study of RAS pathway expression in mice
LOU Li-Li, XIE Liang, HU Yu, CHEN Li-Na, LIANG Ping, SHI Fang, LIU Cai-Jun, LIU Han-Min
Chinese Journal of Contemporary Pediatrics ›› 2020, Vol. 22 ›› Issue (10) : 1119-1124.
PDF(1805 KB)
PDF(1805 KB)
Association of age distribution with the expression of angiotensin-converting enzyme 2 in lung tissues in severe acute respiratory syndrome coronavirus 2 infection: reflections from the study of RAS pathway expression in mice
Objective To study the expression of angiotensin-converting enzyme 2 (ACE2) and other key molecules of the RAS pathway in normal mice at different developmental stages, and to provide ideas for understanding the infection mechanism of coronavirus disease 2019 (COVID-19) as well as the diagnosis and treatment of children with COVID-19. Methods The mice at different developmental stages were enrolled, including fetal mice (embryonic days 14.5 and 18.5), neonatal mice (0, 3, 7, 14, and 21 days old), young mice (28 and 42 days old), and adult mice (84 days old). The lung tissues of all fetal mice from 4 pregnant mice were collected at each time point in the fetal group. Four mice were sampled in other age groups at each time point. Whole transcriptome resequencing was used to measure the mRNA expression of AGT, ACE, ACE2, Renin, Agtr1a, Agtr1b, Agtr2, and Mas1 in mouse lung tissue. Results The expression of ACE2 in the lungs showed changes from embryonic stage to adult stage. It increased gradually after birth, reached a peak on day 3 after birth, and reached a nadir on day 14 after birth (P < 0.05). The expression of AGT reached a peak on days 0 and 7 after birth and reached a nadir on day 21 after birth (P < 0.05). The expression of ACE increased rapidly after birth and reached a peak on day 21 after birth (P < 0.05). Agtr1a expression reached a peak on day 21 after birth (P < 0.05). Agtr2 expression gradually decreased to a low level after birth. Renin, Agtr1b, and Mas1 showed low expression in lung tissues at all developmental stages. Conclusions At different developmental stages of mice, ACE2 has dynamic expression changes, with high expression in early neonatal and adult mice. The other key molecules of the RAS pathway have their own expression patterns. These suggest that the difference in clinical features between children and adults with COVID-19 might be associated with the different expression levels of ACE2 in the different stages, and further studies are needed for the mechanism.
Coronavirus disease 2019 / Severe acute respiratory syndrome coronavirus 2 / Angiotensin-converting enzyme 2 / Mice
[1] COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)[EB/OL].[2020-09-15]. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
[2] 中华人民共和国国家卫生健康委员会疾病预防控制局. 《中国-世界卫生组织新型冠状病毒肺炎(COVID-19)联合考察报告》发布[EB/OL]. (2020-02-29)[2020-03-05]. http://www.nhc.gov.cn/jkj/s3578/202002/87fd92510d094e4b9bad597608f5cc2c.shtml.
[3] 杨斌斌, 朱月玲. 儿童与成人新型冠状病毒肺炎的流行病学与治疗现状分析[J]. 西安交通大学学报(医学版), 2020, 41(4):483-487.
[4] 中华人民共和国国家卫生健康委员会医政医管局. 关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[EB/OL]. (2020-03-04)[2020-03-05]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[5] Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China[J]. Pediatrics, 2020, 145(6):e20200702.
[6] She J, Liu L, Liu W. COVID-19 epidemic:disease characteris-tics in children[J]. J Med Virol, 2020, 92(7):747-754.
[7] Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa[J]. Int J Oral Sci, 2020, 12(1):8.
[8] Baig AM, Khaleeq A, Ali U, et al. Evidence of the COVID-19 virus targeting the CNS:tissue distribution, host-virus interaction, and proposed neurotropic mechanisms[J]. ACS Chem Neurosci, 2020, 11(7):995-998.
[9] Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China[J]. F1000Res, 2020, 9:72.
[10] 刘茜, 王荣帅, 屈国强, 等.新型冠状病毒肺炎死亡尸体系统解剖大体观察报告[J]. 法医学杂志, 2020, 36(1):21-23.
[11] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422.
[12] 王一平, 程在玉. 人与小鼠染色体的同源性及遗传病动物模型[J]. 国外医学(遗传学分册), 1988(2):72-75.
[13] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
[14] Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan:an analysis based on decade-long structural studies of SARS coronavirus[J]. J Virol, 2020, 94(7):e00127-20.
[15] Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019(COVID-19) outbreak-an update on the status[J]. Mil Med Res, 2020, 7(1):11.
[16] 彭文艺, 甘雪晴, 谭艳, 等. 新型冠状病毒感染性疾病心血管系统损害机制与治疗进展[J]. 中华医院感染学杂志, 2020, 30(8):1177-1182.
[17] Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9[J]. Circ Res, 2000, 87(5):E1-E9.
[18] Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase[J]. J Biol Chem, 2000, 275(43):33238-33243.
[19] Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure[J]. Nature, 2005, 436(7047):112-116.
[20] Boskabadi J, Askari VR, Hosseini M, et al. Immunomodulatory properties of captopril, an ACE inhibitor, on LPS-induced lung inflammation and fibrosis as well as oxidative stress[J]. Inflammopharmacology, 2019, 27(3):639-647.
[21] Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2(ACE2) mediates influenza H7N9 virus-induced acute lung injury[J]. Sci Rep, 2014, 4:7027.
[22] Zhang L, Liu Y. Potential interventions for novel coronavirus in China:a systematic review[J]. J Med Virol, 2020, 92(5):479-490.
[23] 孙美丽,杨建民,孙玉萍, 等. RAS抑制剂是治疗新型冠状病毒肺炎的可能选择之一[J]. 中华结核和呼吸杂志, 2020, 43(3):219-222.
[24] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280.e8.
[25] Zhang H, Kang ZJ, Gong HY, et al. Digestive system is a potential route of COVID-19:an analysis of single-cell coexpression pattern of key proteins in viral entry process[J]. Gut, 2020, 69(6):1010-1018.
[26] Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity[J]. Emerg Microbes Infect, 2020, 9(1):469-473.
